Platform and targeted research will progress the scientific state of the art, driven by scientific and industry-led challenges of the area and aim at achieving scientific excellence and leading the way for Next Generation Drug Manufacture.
The ultimate societal benefit of SSPC is to patients, whereby SSPC innovations and process efficiencies have the potential to reduce overall costs and choice of medicines on the market. Additionally, SSPC focuses on process efficiencies and greener chemistry, which has a positive impact on the environment by reducing, and in some cases, eliminating the use of environmentally hazardous materials. SSPC scientists and engineers develop more energy efficient, cleaner, greener methodologies and technologies.
The overarching economic impact objective of the SSPC is the retention, creation and transformation of direct jobs in the pharmaceutical industry in Ireland. Our primary impact is on job retention and increasing the competitiveness of the existing business base in Ireland by supporting its diversification into Research and Development. The economic impact of the platform research programme emanates primarily from
- the development of novel technologies and methodologies leading to patents and high-impact publications
- education/training of industry relevant engineers and scientists
- The individual targeted projects utilise the novel technologies and methodologies developed by the platform research in order to deliver specific solutions to the pharmaceutical industry knowledge gaps identified by the platform research programme. When the deliverables of the targeted projects are adopted/implemented by industry the economic impact will materialise as:
- Manufacturing productivity impacts, including reduction in input materials costs, time savings in production processes, and reduction in environmental waste costs
- R&D cycle development impacts, including reduction in process R&D costs, and time savings in process development cycles
- Portfolio impacts, including increased turnover due to expanded product portfolios.
One of the key aims at SSPC is to enable productive participation and strategic partnerships with all stakeholders. Success relies on key efforts made by academia and the pharmaceutical industry working together. SSPC’s operations team helps facilitate such collaboration by conducting informal project evaluations, discussions, project meetings, strand meetings and face-to-face meetings at quarterly technical meetings every year. The quarterly technical meetings, project meetings, workshops, conferences, training and other networking events hosted by SSPC every year are critical knowledge transfer mechanisms. The appointment of project sponsors and champions has been a key addition to the existing mechanisms for knowledge exchange.
SSPC prides itself on being one of the very few centres who accommodate all partners to meet regularly and assess the interactions between, and the innovations of, each individual project and strand. By facilitating and coordinating the interaction between key stakeholders, engagement at this level nurtures opportunity. In addition, it offers frequent review of research and also a platform for students to attend and present their work.